[Correspondence] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

Wen-Zhao Zhong and colleagues' trial1 shows that adjuvant gefitinib led to 28 ·7 months (95% CI 24·9–32·5) of disease-free survival, compared with 18·0 months (13·6–22·3) with vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer (NSCLC) (hazard ratio [HR] 0·60, 95% CI 0·42–0·87; p=0·00 54). However, several caveats should be kept in mind. First, disease-free survival was much shorter than in other trials of adjuvant vinorelbine plus cisplatin in resected NSCLC.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Rafael Rosell, Niki Karachaliou Tags: Correspondence Source Type: research